Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx
Imugene Ltd (ASX:IMU) and Medical University Vienna have presented positive new data on the PD-1 mimotope cancer vaccine program at the American Association for Cancer Research (AACR) 2019 Annual Meeting.
The presentation by Dr Joshua Tobias from the Medical University Vienna was entitled ‘PD1 B cell mimotopes with functional PD1-PDL1 blocking capacity and anti-tumor activity: New strategy for a multi-level cancer immunotherapy.’
@TeamImugene and MedUni Vienna mimotope vaccines inhibit tumor growth in HER-2+ breast cancer models READ today’s ASX news https://t.co/UDejcS62wj $IMU #CancerVaccine #BreastCancer #ImmunoOncology (ASX:IMU) pic.twitter.com/VRyJLdWtMY
— Imugene | Cancer Immunotherapies (@TeamImugene) April 2, 2019
Imugene’s PD-1 B-cell vaccine, known as KEY-Vaxx, aims to induce the body to produce antibodies that block PD-1 signalling, and thus produce an anticancer effect.
The research led by Professor Ursula Wiedermann from the Medical University Vienna successfully inhibited tumor growth in a syngeneic mouse model of HER-2+ breast cancer via both passive and active immunisation strategies with PD-1 targeting B-cell cancer vaccines.
READ: Imugene gets development roadmap for cancer vaccine from FDA meeting
For the active immunisation study, which is of greatest interest and potential value to cancer researchers, the surrogate vaccine derived from mouse PD-1 was able to “brake tolerance” thereby inducing a sustained antibody response to the self-protein PD-1.
Importantly, the findings provide proof of concept and validation for Imugene’s human PD-1 cancer vaccine KEY-Vaxx.
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/217820/imugene-presents-positive-new-data-validating-its-human-cancer-vaccine-key-vaxx-217820.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Lion’s Mane Mushroom
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes:
Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.
Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.
Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.
Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.
Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules. Today Be 100% Satisfied Or Receive A Full Money Back Guarantee Order Yours Today By Following This Link.